trial

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms

NCTId NCT02013531
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 37 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2014-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
37 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2013-11
Primary completion
2014-05
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Brexpiprazole (Rexulti)

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.Collaborator

Investigators

1
Jun-ichi Hashimoto, PhDStudy Director

Sites

0 total

Linked catalysts

1
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depres — primary completion2014-05

Facts & assertions

4 sourced
Enrollment
37
Phase
PHASE3
Primary Completion Date
2014-05
Status
COMPLETED
relationships
The graph out of here
drug
Brexpiprazole (Rexulti)
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
collaborator
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Major Depressive Disorder
indication
Depressive Disorder, Major
indication
Psychotic Disorders
indication
investigator
Jun-ichi Hashimoto, PhD
person